A comparative pharmacokinetic evaluation of two aqueous progesterone 25 mg injections in healthy postmenopausal women under fasting conditions: An open‐label, balanced, randomized, two‐treatment, two‐period, two‐sequence, single‐dose, crossover bioequivalence study
Clinical Pharmacology in Drug Development · 2026
DOI: 10.1002/cpdd.70025 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Noopur Vyas und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sun Pharma Laboratories Ltd., Mumbai, India. Hauptthemen laut MEDLINE: Progesterone, Postmenopause, Fasting. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sun Pharma Laboratories Limited, India.
Abstract (Originalsprache)
The growing demand for assisted reproductive technology (ART) has increased the need for effective luteal phase support. Progesterone, essential for maintaining early pregnancy, is a critical component of ART. This open‐label, balanced, randomized, two‐treatment, crossover, single‐dose study compared the bioequivalence of aqueous progesterone 25 mg injection (AqSusten ® [Test, Sun Pharma Laboratories Limited]), compared to the innovator's aqueous progesterone 25 mg injection (Lubion ® [Reference, IBSA Farmaceutici Italia Srl]), in healthy postmenopausal women under fasting conditions. Forty‐eight subjects received either treatment in Period 1, followed by alternate treatment in Period 2, with a 14‐day washout period. Pharmacokinetics ( C max , AUC 0–t , AUC 0‐∞ ) and mean plasma concentration–time profiles were assessed. Forty‐five subjects completed the study. Pharmacokinetic data for both products were comparable, with percentage ratios for AUC 0–t , AUC 0−∞ , and C max of 99.16%, 98.78%, and 103.36%, respectively, within the acceptable bioequivalence range of 80%‐125%. Plasma concentration–time profiles were similar, and no serious adverse events were reported. Mild adverse events with Lubion ® included increased white blood cell count and blood glucose. AqSusten ® demonstrated bioequivalence to Lubion ® in healthy postmenopausal women under fasting conditions. Both formulations exhibited similar pharmacokinetic profiles, with favorable safety and tolerability, suggesting AqSusten ® as a viable alternative in ART treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sun Pharma Laboratories Ltd., Mumbai, India.
- Sun Pharmaceutical Industries Ltd., Vadodara, India.
Förderung
- Sun Pharma Laboratories Limited, India
Zitieren
APA
Vyas, N., Chakra, A., Sarode, P., Dharmadhikari, S., Puppalwar, G., Khandhedia, C., Mane, A., Goyani, A., & Khopade, A. J. (2026). A comparative pharmacokinetic evaluation of two aqueous progesterone 25 mg injections in healthy postmenopausal women under fasting conditions: An open‐label, balanced, randomized, two‐treatment, two‐period, two‐sequence, single‐dose, crossover bioequivalence study. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70025
Vancouver
Vyas N, Chakra A, Sarode P, Dharmadhikari S, Puppalwar G, Khandhedia C, et al. A comparative pharmacokinetic evaluation of two aqueous progesterone 25 mg injections in healthy postmenopausal women under fasting conditions: An open‐label, balanced, randomized, two‐treatment, two‐period, two‐sequence, single‐dose, crossover bioequivalence study. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70025
BibTeX
@article{Vyas2026,
author = {Vyas, Noopur and Chakra, Amaresh and Sarode, Prashant and Dharmadhikari, Shruti and Puppalwar, Gaurav and Khandhedia, Chintan and Mane, Amey and Goyani, Alpesh and Khopade, Ajay Jaysingh},
title = {A comparative pharmacokinetic evaluation of two aqueous progesterone 25 mg injections in healthy postmenopausal women under fasting conditions: An open‐label, balanced, randomized, two‐treatment, two‐period, two‐sequence, single‐dose, crossover bioequivalence study},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
doi = {10.1002/cpdd.70025}
}
EUVIMED